OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Ltd has reported a Q1 FY25 revenue of $0.166 million, marking significant growth from the previous year, driven by the expanding commercialization of their OncoSil™ device for pancreatic cancer treatment. The company made notable achievements this quarter, including the first successful surgical resection in Türkiye following OncoSil™ treatment and substantial progress in clinical trials and market presence in Spain. Furthermore, a $2.7 million investment from an Australian institution highlights confidence in OncoSil’s potential for future growth.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.